ACCESS Newswire·Nov 3, 2025, 4:05 PM ET

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Protagonist Therapeutics will present four clinical data sets regarding rusfertide for polycythemia vera at the 67th ASH Annual Meeting in Orlando, Florida, from December 6-9, 2025.
An oral session on Saturday, December 6, will feature Phase 3 VERIFY study results on response durability & safety through week 52, presented by Andrew Kuykendall, MD.
Two poster presentations on Monday, December 8, will cover patient-reported outcomes (presented by Aniket Bankar, MD) & dermatologic examination observations (presented by Joseph Shatzel, MD) from the VERIFY study.
A poster presentation on Sunday, December 7, will share initial results from the Phase 2 THRIVE Extension study on long-term rusfertide treatment, presented by Naveen Pemmajaru, MD.
All presentations are scheduled at the Orlando Convention Center under the Myeloproliferative Syndromes session.
Protagonist Therapeutics expects to submit its New Drug Application for rusfertide by the end of 2025, following a collaboration with Takeda Pharmaceuticals.
The company previously submitted an NDA for its IL-23R antagonist icotrokinra to the FDA in July 2025.
Rusfertide is a hepcidin mimetic being developed for polycythemia vera, while icotrokinra was licensed to Janssen Biotech, Inc. following early-stage development by Protagonist.